Metastatic anal cancer represents a challenging stage of the disease where cancer cells have spread from the anal canal to distant organs such as the liver or lungs. While treatment options for early-stage anal cancer are well established, managing the disease once it has spread requires a different approach focused on slowing progression, controlling symptoms, and maintaining quality of life.

Understanding Treatment Goals When Cancer Has Spread

When anal cancer reaches the metastatic stage, meaning it has traveled to other parts of the body, the focus of treatment shifts. At this point, the cancer can be any size and may have also spread to nearby lymph nodes. Common sites where metastatic anal cancer appears include the liver, lungs, lymph nodes around the rectum, groin and pelvis, as well as the bladder, urethra, vagina, prostate, and bones.^[7]

Between 10 and 20 percent of people with anal cancer present with metastatic disease at their initial diagnosis.^[3][9] For these patients, and for those whose cancer returns after initial treatment, the main goals become managing symptoms, slowing the cancer’s growth, and helping patients maintain the best possible quality of life. Unlike localized anal cancer, where the combination of radiation and chemotherapy can often cure the disease, metastatic anal cancer remains more difficult to control with current treatments.

Treatment decisions depend on several factors including where exactly the cancer has spread, how many sites are involved, the patient’s overall health and fitness level, and whether they have other medical conditions such as HIV (human immunodeficiency virus) that affects the immune system. Some patients may have only one or a few metastatic spots, while others have more widespread disease, and this influences which treatment approach doctors recommend.

Standard Treatment Approaches for Metastatic Disease

The primary treatment recommended for metastatic anal cancer is systemic chemotherapy, which means anti-cancer drugs that circulate throughout the entire body via the bloodstream. These medications are designed to destroy cancer cells wherever they may be located.^[3][9] The National Comprehensive Cancer Network, an organization of leading cancer centers in the United States, recognizes that while there is limited data to guide treatment decisions for metastatic anal cancer, some evidence suggests specific chemotherapy combinations as the initial choice outside of clinical trials.

The most commonly used first-line chemotherapy regimen combines fluoropyrimidine drugs with cisplatin. Fluoropyrimidines are a class of chemotherapy drugs that interfere with cancer cells’ ability to grow and divide. The specific fluoropyrimidine used is typically 5-fluorouracil, often abbreviated as 5-FU. This drug is usually given through a vein as a continuous infusion over several days. Cisplatin is a platinum-based chemotherapy drug that damages the DNA inside cancer cells, preventing them from multiplying.^[3][9]

One standard treatment schedule involves giving cisplatin at a dose of 60 to 75 milligrams per square meter of body surface area on the first day, combined with 5-FU given as a continuous infusion at 750 to 1000 milligrams per square meter per day for four consecutive days. This cycle is then repeated every three to four weeks, depending on the specific protocol and how well the patient tolerates the treatment.^[11]

An alternative to 5-FU is capecitabine, which is taken by mouth as a pill rather than given through an intravenous line. Capecitabine is converted into 5-FU inside the body, so it works in a similar way but offers the convenience of oral administration. This can be particularly helpful for patients who prefer not to have extended hospital or clinic visits for continuous infusions.

When patients do not respond to the initial cisplatin and fluoropyrimidine combination, or if the cancer progresses after initially responding, doctors may try other chemotherapy regimens. One option is mFOLFOX, which combines oxaliplatin (another platinum-based drug), leucovorin (a vitamin that enhances 5-FU’s effectiveness), and 5-FU. This regimen involves oxaliplatin at 85 milligrams per square meter, leucovorin at 400 milligrams per square meter, and 5-FU given both as a quick injection and as a 46-48 hour continuous infusion, repeated every two weeks.^[11]

Another second-line option combines carboplatin with paclitaxel. Carboplatin is similar to cisplatin but often has fewer side effects, particularly less kidney damage and nausea. Paclitaxel is a different type of chemotherapy drug that works by preventing cancer cells from dividing. This combination is given every three weeks, with dosing calculated based on body surface area and kidney function.^[11]

Managing Side Effects of Standard Chemotherapy

Chemotherapy affects both cancer cells and some normal cells in the body, which leads to side effects. The severity and type of side effects vary from person to person and depend on which drugs are used. Common side effects of cisplatin and 5-FU include nausea and vomiting, fatigue, decreased blood cell counts leading to increased infection risk and anemia, mouth sores, diarrhea, and kidney problems with cisplatin specifically.

Oxaliplatin can cause numbness and tingling in the hands and feet, a condition called peripheral neuropathy. This sensation can be triggered or worsened by cold temperatures. Paclitaxel can also cause neuropathy as well as muscle and joint pain. Carboplatin tends to cause less nausea than cisplatin but can significantly lower blood cell counts.

Healthcare teams work closely with patients to manage these side effects through medications that prevent nausea, antibiotics if infections develop, blood transfusions if needed, and dose adjustments when side effects become too severe. Patients receiving chemotherapy require regular blood tests to monitor their blood cell counts and kidney and liver function.

Supportive and Palliative Care

For patients who are not fit enough to tolerate aggressive chemotherapy, or when the cancer continues to grow despite treatment, doctors may recommend best supportive care, also called palliative care. This approach focuses on relieving symptoms and improving quality of life rather than trying to shrink the cancer.^[4]

Supportive care can include radiation therapy directed at specific areas causing pain or other symptoms, such as bone metastases or masses pressing on nerves or organs. It may also involve surgery to address complications like bowel obstruction. Pain management, nutritional support, and psychological counseling are also important components of supportive care.

Treatment Being Tested in Clinical Trials

Because standard chemotherapy options for metastatic anal cancer are limited and not always effective, researchers are actively investigating new treatment approaches through clinical trials. These studies test whether newer medications or treatment strategies might work better than current options or provide alternatives when standard treatments fail.

Immunotherapy Approaches

One of the most promising areas of research involves immunotherapy, a type of treatment that helps the patient’s own immune system recognize and attack cancer cells. Metastatic anal cancer that has stopped responding to standard chemotherapy may be treated with immunotherapy drugs called checkpoint inhibitors.

Two checkpoint inhibitors that have shown promise are nivolumab and pembrolizumab. These drugs work by blocking proteins called PD-1 on immune cells. When PD-1 is blocked, it prevents cancer cells from “hiding” from the immune system, allowing T cells (a type of white blood cell) to recognize and destroy the cancer. Nivolumab can be given at a dose of 240 milligrams intravenously every two weeks or 480 milligrams every four weeks. Pembrolizumab is typically administered at 200 milligrams every three weeks or 400 milligrams every six weeks, continuing until the disease progresses, side effects become unacceptable, or for up to 24 months if the cancer remains stable.^[11]

These immunotherapy drugs represent treatment options after patients have already tried and failed more standard chemotherapy regimens. They are being studied because many anal cancers are associated with HPV infection, and HPV-related cancers sometimes respond well to immunotherapy. However, not all patients benefit from these drugs, and researchers are working to identify which patients are most likely to respond.

Side effects of checkpoint inhibitors are different from traditional chemotherapy. Rather than directly killing cells, these drugs can cause the immune system to become overactive and attack normal tissues, leading to what are called immune-related adverse events. These can affect various organs including the lungs, liver, intestines, hormone-producing glands, and skin. While most immune-related side effects are manageable, some can be serious and require treatment with medications that suppress the immune system.

EGFR Inhibitors

Another area of investigation involves drugs that target the epidermal growth factor receptor, commonly abbreviated as EGFR. This protein sits on the surface of cells and, when activated, sends signals that tell cells to grow and divide. Many cancer cells have excessive amounts of EGFR or mutated versions that are constantly active, driving uncontrolled growth.

EGFR inhibitors are medications that block this receptor, preventing the growth signals from getting through. Early reports of treating metastatic anal cancer patients with EGFR inhibitors have been encouraging, suggesting these drugs might offer another option when standard chemotherapy is not working.^[9] However, these treatments are still being studied in clinical trials to determine their effectiveness and optimal use.

Combined Approaches: Chemotherapy Plus Local Treatment

Researchers are also exploring whether combining systemic chemotherapy with local treatments directed at specific metastatic sites might improve outcomes for selected patients. This approach is inspired by strategies used in metastatic colorectal cancer, where removing isolated liver metastases through surgery has proven beneficial for some patients.

Several case reports and small case series have described patients with metastatic anal cancer who received systemic chemotherapy followed by surgery to remove solitary or limited metastases in the liver, and then underwent radiation therapy to the original anal tumor site. In some of these cases, patients achieved long periods without disease progression and experienced good symptom control without increased toxicity.^[14][21]

For example, one reported case involved a patient who received initial chemotherapy with cisplatin and 5-FU, which shrank the cancer, followed by surgical removal of a liver metastasis, and then chemoradiotherapy (radiation combined with chemotherapy using 5-FU and mitomycin) directed at the primary anal cancer. This patient remained disease-free 19 months after diagnosis with no increased side effects from the combined approach.^[14]

Another case described a woman with stage IV anal cancer and liver metastases who was treated with a similar multi-step approach: initial chemotherapy to shrink the cancer, liver resection surgery, followed by chemoradiotherapy to the anal area. This patient achieved complete response and long-term survival.^[21]

It is important to emphasize that this combined strategy involving surgery for metastases is not standard treatment and is only considered appropriate for very carefully selected patients. Factors that might make a patient suitable for this approach include having only one or very few metastatic spots, good response to initial chemotherapy, good overall health and fitness for surgery, and the technical feasibility of completely removing all visible cancer. This approach is still being studied and is not appropriate for all or even most patients with metastatic anal cancer.

Clinical Trial Phases and What They Mean

When new treatments are being developed, they go through a series of testing phases. Phase I trials are the first studies in humans and primarily focus on determining whether a new drug is safe, what dose should be used, and what side effects occur. These trials typically involve small numbers of patients.

Phase II trials enroll more patients and aim to determine whether the new treatment actually works against the cancer—does it shrink tumors or slow their growth? These studies also continue to monitor for side effects and safety.

Phase III trials are large studies that compare the new treatment directly against the current standard treatment to see which works better. These trials provide the strongest evidence about whether a new therapy should become a new standard of care.

Patients interested in participating in clinical trials should discuss this option with their healthcare team. Clinical trials can provide access to promising new treatments before they become widely available. Information about eligibility criteria, trial locations, and how to enroll is typically available through cancer centers and online trial registries.

Most Common Treatment Methods

• Chemotherapy
  • Cisplatin combined with 5-fluorouracil is the most common first-line treatment for metastatic anal cancer
  • Capecitabine may be substituted for 5-FU and offers the convenience of oral administration
  • Second-line options include mFOLFOX (oxaliplatin, leucovorin, and 5-FU) or carboplatin with paclitaxel
  • Chemotherapy cycles are typically repeated every 2-4 weeks depending on the specific regimen
• Immunotherapy
  • Nivolumab and pembrolizumab are checkpoint inhibitors used after standard chemotherapy fails
  • These drugs help the immune system recognize and attack cancer cells by blocking PD-1 protein
  • Treatment continues until disease progression, unacceptable side effects, or up to 24 months
  • Not all patients respond to immunotherapy and research continues to identify who benefits most
• EGFR Inhibitors
  • Target the epidermal growth factor receptor on cancer cells to block growth signals
  • Early reports suggest potential benefit in metastatic anal cancer patients
  • Still being studied in clinical trials to determine effectiveness and optimal use
• Combined Systemic and Local Treatment
  • For selected patients with limited metastases, especially solitary liver metastases
  • Involves initial chemotherapy followed by surgical removal of metastases
  • May include subsequent chemoradiotherapy directed at the primary anal tumor
  • Requires careful patient selection based on extent of disease, response to chemotherapy, and overall fitness
  • Not standard treatment but has shown promise in case reports and small series
• Best Supportive Care
  • Focuses on symptom relief and quality of life rather than cancer shrinkage
  • May include radiation therapy for painful bone metastases or masses causing symptoms
  • Surgery to address complications like bowel obstruction
  • Pain management, nutritional support, and psychological counseling
  • Recommended for patients not fit enough for aggressive chemotherapy